Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations
Current first-line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Authors
- Lung‐Yi Loey Mak
- Tsung‐Hui Hu
- Desmond Y. H. Yap
Institutions
- Queen Mary Hospital (CN)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- University of Hong Kong (HK)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1111/apt.70560
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences